Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
22/12/2023 13:08
Dec 22 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS RECEIVES HREC APPROVAL TO INITIATE
PHASE 1
CLINICAL TRIAL OF NASH AND OBESITY DRUG
Source text for Eikon: ID:nBw3TzMm5a
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment